放射性核素标记前列腺特异膜抗原配体对转移性去势抵抗性前列腺癌诊治的研究进展

摘要

前列腺癌是男性患者最常见的癌症.晚期前列腺癌会进展为转移性去势抵抗性前列腺癌(mCRPC),其诊疗一直是医学界的难题.应用放射性核素标记前列腺特异膜抗原(PSMA)配体对mCRPC癌灶进行诊断和靶向定位治疗,可以明显改善患者预后,提高生存质量,有较大的潜在临床应用价值.该文对近年来放射性核素标记PSMA配体在mCRPC单光子显像、正电子显像、治疗及诊治一体化中的研究进展进行综述.%Prostate cancer is the most common cancer among males. Advanced prostate cancer could develop into metastatic castration-resistant prostate cancer (mCRPC), which is a challenge in the di-agnosis and treatment. The prognosis and quality of life of patients can be significantly improved by using ra-diolabeled prostate-specific membrane antigen ( PSMA) ligands for localization and targeted therapy of mCRPC. This review summarizes the research progress of radiolabeled PSMA ligands in theranostics of mCRPC including SPECT imaging, PET imaging, and brachytherapy.